OakChart

Cardio Diagnostics Holdings Inc

CDIOHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

1.92+0.06 (3.23%)
2026-11-11 23:21 CET
Market cap
5.50 USD m
Revenue, TTM
0.02 USD m
Net income, TTM
-6.49 USD m
Free cash flow, TTM
-5.78 USD m
EPS diluted, TTM
-2.52
P/E
-
Compare

Price

CDIO against its 20, 50 and 200-day averages
2050200
1.502.002.503.00619K1.2MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CDIOclose 1.9220-day 1.7250-day 1.84200-day 2.061.92

75.7% under the 52-week high of 7.91 on 27 Feb 2026. 52-week low 0.97 on 6 Feb 2026. Last 15 sessions, 23.7% high to low

Volume 0.27× normal · the line is the 50-bar volume average

Profile

CDIO
52-week range, 14% of the way up
0.977.91

Cardio Diagnostics Holdings, Inc. engages in the provision of medical diagnostic testing services. It also develops and commercializes a series of products for major types of cardiovascular disease and associated comorbidities, including coronary heart disease (CHD), stroke, heart failure, and diabetes. The company was founded by Meeshanthini V. Dogan and Robert Philibert in 2017 and is headquartered in Chicago, IL.

Employees15
IPOJan 14, 2022
Beta2.26
ATR, 14d0.11
Rel volume0.27
Short float0.17%
Insider own4.34%
Inst own6.52%

Snapshot

6 groups

Valuation

Index-
Market Cap5.68M
Enterprise Value1.98M
Income-6.49M
Sales0.02M
Book/sh1.93
Cash/sh1.33
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees15
IPOJan 14, 2022

Ratios

P/E-
Forward P/E-
PEG-
P/S283.87
P/B0.99
P/C1.44
P/FCF-
EV/EBITDA-
EV/Sales98.87
Quick Ratio17.44
Current Ratio17.44
Debt/Eq0.04
LT Debt/Eq0.02
Option/ShortNo / Yes

Earnings

EPS (ttm)-2.52
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y56.57% 30.61%
Sales past 3/5Y149.89% 101.40%
EPS Y/Y TTM35.35%
Sales Y/Y TTM-3.78%
EPS Q/Q39.98%
Sales Q/Q25.74%
Earnings-
EPS/Sales Surpr.0.00% 0.00%

Ownership

Insider Own4.34%
Insider Trans0.00%
Inst Own6.52%
Inst Trans-4.39%
ROA-87.24%
ROE-93.55%
ROIC-111.19%
Gross Margin-2231.90%
Oper. Margin-42649.75%
Profit Margin-42721.93%
SMA2011.77%
SMA504.17%
SMA200-6.96%
Trades-

Technical

Shs Outstand2.96M
Shs Float2.83M
Short Float0.17%
Short Ratio0.14
Short Interest0.00M
52W High7.91 -75.73%
52W Low0.97 97.94%
Volatility7.74% 6.80%
ATR (14)0.11
RSI (14)61.08
Beta2.26
Rel Volume0.27
Avg Volume35.71K
Volume9,621

Performance

Perf Week16.72%
Perf Month9.71%
Perf Quarter-4.48%
Perf Half Y7.26%
Perf YTD-29.15%
Perf Year-49.61%
Perf 3Y-93.73%
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price60.00
Prev Close1.86
Price1.92
Change %3.23%

Peers

Mkt cap
TickerCompanyMkt cap
VNRXVolitionRX Ltd5.69M
BIAFBioAffinity Technologies Inc4.41M
PRPOPrecipio Inc44.40M
MDXHMDxHealth SA13.98M
IMDXInsight Molecular Diagnostics Inc78.21M
XGNExagen Inc121.98M
BDSXBiodesix Inc112.22M
CSTLCastle Biosciences Inc1.05B
MYGNMyriad Genetics Inc548.68M
ISPCiSpecimen Inc1.79M

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2024Q42025-02-26-1.800-1.800-0.9920.030.031
2024Q32024-11-27-1.800-1.800-1.7340.010.011
2024Q22024-08-28-1.800-1.800-1.7090.010.011
2024Q12024-05-29-6.000-2.700-5.9260.020.052
2023Q42024-02-28-2.100-4.050-2.0290.010.252
2023Q32023-11-29-4.800-8.250-4.8700.010.012
2023Q22023-08-30-11.700-11.700-11.7830.000.001
2023Q12023-08-28-3.300--3.2450.00-2
2022Q42023-05-23-9.300--13.0790.00-1
2022Q32022-11-30-19.800-19.8000.7470.100.101
2022Q22022-10-06-15.900--1.8190.00--
2025Q1---1.800-0.970-0.051
2025Q2---1.800-0.968-0.081
2025Q3---1.800-0.975-0.151
2025Q4---1.800-0.803-0.251

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2022FY-45.300-26.100-45.2860.000.50
2023FY-19.800-23.250-19.8000.010.14
2024FY-10.800-10.800-9.3520.060.06
2025FY--6.900-3.710-0.53

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2025Q1S2025-02-261000.050.050.05
2025Q1S2024-11-271000.050.050.05
2025Q1S2024-11-091000.050.050.05
2025Q1S2024-08-281100.050.050.05
2025Q1S2024-08-261100.050.050.05
2025Q1S2024-08-181000.000.000.00
2025Q1S2024-06-041010.000.000.00
2025Q1S2024-05-291010.350.350.35
2025Q1S2024-04-181010.350.350.35
2025Q1R2025-02-26100-0.06-0.06-0.06
2025Q1R2024-11-27100-0.06-0.06-0.06
2025Q1R2024-11-09100-0.06-0.06-0.06
2025Q1R2024-08-28110-0.06-0.06-0.06
2025Q1R2024-08-26110-0.06-0.06-0.06

Estimate history

EPS, annual-16.002-45.286-19.811-9.352-3.71-2.5246
Period20212022202320242025TTM
EPS, quarterly-1.734-0.992-0.97-0.968-0.975-0.803-0.63-0.507-0.585
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0.0010.0010.0170.0350.0150.02
Period20212022202320242025TTM
Sales, quarterly0.0070.0050.0010.0070.0030.0040.0030.0050.004
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.0410.3170.6851.5311.8262.959
Period20212022202320242025MRQ
Shares, quarterly1.0111.5311.7391.741.7671.8262.9592.9592.959
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Total Revenue0.020.010.030.020.000.00
Cost of Goods Sold Incl. D&A0.350.400.280.110.020.00
Gross Profit-0.34-0.38-0.24-0.09-0.020.00
Selling, General and Administrative Excl. Other6.146.108.127.154.530.61
Research and Development0.750.640.030.150.040.03
Other Operating Expense0.000.000.000.000.000.00
Operating Income-6.48-6.48-8.37-7.24-4.55-0.62
Interest Expense0.010.010.026.74-0.00
Unusual Expense0.000.000.00-5.600.000.00
Net Income Before Taxes-6.49-6.50-8.38-8.38-4.66-0.62
Income Taxes0.000.000.000.000.000.00
Consolidated Net Income-6.49-6.50-8.38-8.38-4.66-0.62
Net Income From Continuing Operations-6.49-6.50-8.38-8.38-4.66-0.62
Net Income-6.49-6.50-8.38-8.38-4.66-0.62
EPS (Recurring)-2.19-3.71-9.35-29.08-45.29-16.00
EPS (Basic, Before Extraordinaries)-2.52-3.71-9.35-19.81-45.29-16.00
EPS (Diluted)-2.52-3.71-9.35-19.81-45.29-16.00
EBITDA-6.12-6.09-8.09-7.13-4.53-0.60
Non-Operating Income (Expense)0.000.000.000.00-0.110.00
Other After Tax Adjustments0.000.000.000.000.000.00
Price To Sales Ratio370.30320.16706.811,850.923,445.20-
Gross Margin-2,231.90-2,585.52-692.05-554.09-1,584.210.00
Operating Margin-42,649.75-43,737.46-23,977.86-42,440.43-478,784.32-68,862.15
Net Margin-42,721.93-43,832.49-24,028.24-49,087.81-490,630.00-68,862.15
Shares Outstanding2.961.831.530.680.320.04
Market Capitalization5.505.5042.1332.668.618.61

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.010.000.000.000.010.000.00
Cost of Goods Sold Incl. D&A0.050.050.090.160.090.090.130.08
Gross Profit-0.05-0.04-0.09-0.16-0.09-0.08-0.12-0.08
Selling, General and Administrative Excl. Other1.681.451.691.311.621.601.511.44
Research and Development0.170.160.130.290.190.010.000.01
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-1.73-1.50-1.78-1.46-1.71-1.68-1.63-1.52
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-1.73-1.50-1.79-1.47-1.71-1.68-1.64-1.52
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-1.73-1.50-1.79-1.47-1.71-1.68-1.64-1.52
Net Income From Continuing Operations-1.73-1.50-1.79-1.47-1.71-1.68-1.64-1.52
Net Income-1.73-1.50-1.79-1.47-1.71-1.68-1.64-1.52
EPS (Recurring)-0.59-0.51-0.63-0.80-0.98-0.97-0.97-0.99
EPS (Basic, Before Extraordinaries)-0.59-0.51-0.63-0.80-0.98-0.97-0.97-0.99
EPS (Diluted)-0.59-0.51-0.63-0.80-0.98-0.97-0.97-0.99
EBITDA-1.68-1.45-1.69-1.30-1.62-1.59-1.51-1.43
Non-Operating Income (Expense)0.000.000.000.000.000.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.020.020.02-0.02---
Price To Sales Ratio370.30448.53334.41333.80446.66320.94838.761,207.53
Gross Margin-1,300.03-830.52-3,431.79-4,381.29-3,037.93-1,092.55-13,231.91-1,769.95
Operating Margin-48,193.84-27,950.50-66,598.40-41,159.55-59,950.86-22,457.51-173,463.83-33,608.20
Net Margin-48,254.35-28,012.46-66,722.31-41,219.92-60,053.80-22,517.71-173,942.98-33,672.61
Shares Outstanding2.962.962.961.831.771.741.741.53
Market Capitalization5.506.485.774.957.076.2617.2142.13

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY
Cash & Short Term Investments5.117.831.284.120.51
Short Term Receivables0.010.020.260.000.00
Inventories0.000.000.000.000.00
Other Current Assets0.800.941.221.770.29
Total Current Assets5.928.792.775.890.80
Net Property, Plant & Equipment0.961.111.150.000.00
Total Investments and Advances0.000.000.000.000.00
Intangible Assets0.870.710.540.360.30
Deferred Tax Assets6.77----
Other Assets0.010.010.010.000.00
Total Assets14.5310.624.466.251.10
Short Term Debt Incl. Current Port. of LT Debt0.510.540.600.850.00
Accounts Payable0.100.090.241.100.03
Other Current Liabilities0.000.000.000.000.00
Total Current Liabilities0.600.630.841.950.03
Long Term Debt0.190.430.660.000.00
Provision for Risks Charges0.000.000.000.000.00
Deferred Tax Liabilities6.77----
Other Liabilities0.000.000.000.000.00
Total Liabilities7.561.061.501.950.03
Non-Equity Reserves0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00
Common Equity6.979.562.964.301.07
Total Shareholders Equity6.979.562.964.301.07
Accumulated Minority Interest0.000.000.000.000.00
Total Equity6.979.562.964.301.07
Total Liabilities & Stockholders Equity14.5310.624.466.251.10
Book Value Per Share3.826.244.3213.5626.00
Tangible Book Value Per Share3.345.783.5412.4318.74
Full-Time Employees1513981
Price to Book Ratio0.964.4114.280.130.13
Return on Assets-51.68-111.20-156.40-12.94-
Return on Equity-78.62-133.96-230.77-13.32-
Return on Invested Capital-90.74-83.97-231.33-108.35-58.09
Quick Ratio9.7913.923.293.0223.71
Current Ratio9.7913.923.293.0223.71

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Net Income-6.49-6.50-8.38-8.38-4.66-0.62
Depreciation0.380.400.280.110.020.02
Other Funds (Non Cash)0.100.112.592.380.110.06
Funds from Operations-6.01-5.99-5.52-5.88-4.53-0.55
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.230.260.520.21-0.56-0.04
Cash from Operating Activities-5.78-5.73-4.99-5.67-5.09-0.59
Capital Expenditures-0.25-0.42-0.40-0.77-0.08-0.11
Net Assets From Acquisitions0.000.000.000.000.00-0.25
Sale of Fixed Assets and Businesses0.000.000.000.000.140.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.00-0.02-0.430.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.25-0.42-0.40-0.79-0.37-0.36
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock3.963.8012.550.3911.991.23
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock3.963.8012.550.3911.991.23
Proceedsfrom Stock Options3.690.000.000.0011.991.23
Issuance or Reduction of Debt, Net-0.34-0.37-0.453.56-0.190.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.00-0.15-0.32-2.730.00
Other Financing Activities Uses0.000.00-0.15-0.32-2.730.00
Cash from Financing Activities3.623.4311.943.639.061.23
Net Change in Cash-2.41-2.726.54-2.833.600.28
Free Cash Flow-5.78-5.91-5.21-6.25-5.09-0.59
Preferred Dividends (Cash Flow)-0.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments3.945.597.085.116.367.97
Short Term Receivables0.000.000.000.010.010.01
Inventories0.000.000.000.000.000.00
Other Current Assets0.410.570.660.800.560.72
Total Current Assets4.356.167.745.926.938.70
Net Property, Plant & Equipment0.690.780.870.961.050.97
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets1.030.970.930.870.800.71
Deferred Tax Assets---6.77--
Other Assets0.010.010.010.010.010.01
Total Assets6.087.939.5614.538.7910.40
Short Term Debt Incl. Current Port. of LT Debt0.120.230.370.510.250.32
Accounts Payable0.130.130.120.100.150.05
Other Current Liabilities0.00-0.000.000.000.000.00
Total Current Liabilities0.250.360.490.600.400.37
Long Term Debt0.120.140.160.190.240.30
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---6.77--
Other Liabilities0.000.000.000.000.000.00
Total Liabilities0.370.500.667.560.640.67
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity5.727.438.906.978.159.72
Total Shareholders Equity5.727.438.906.978.159.72
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity5.727.438.906.978.159.72
Total Liabilities & Stockholders Equity6.087.939.5614.538.7910.40
Book Value Per Share1.932.513.013.824.615.59
Tangible Book Value Per Share1.592.182.693.344.165.18
Full-Time Employees---15--
Price to Book Ratio0.960.730.510.590.720.55
Return on Assets-87.24-70.62-60.90-51.68-98.75-86.85
Return on Equity-93.55-75.44-65.59-78.62-110.70-97.67
Return on Invested Capital-29.69-19.84-19.72-20.46-20.43-16.79
Quick Ratio17.4417.1515.769.7917.3923.55
Current Ratio17.4417.1515.769.7917.3923.55

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-1.73-1.50-1.79-1.47-1.71-1.68
Depreciation0.100.100.090.090.090.09
Other Funds (Non Cash)0.020.020.020.020.020.03
Funds from Operations-1.61-1.38-1.67-1.35-1.60-1.56
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.100.040.11-0.010.21-0.01
Cash from Operating Activities-1.52-1.34-1.56-1.36-1.39-1.57
Capital Expenditures-0.06-0.05-0.06-0.08-0.26-0.04
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.06-0.05-0.06-0.08-0.26-0.04
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.003.690.260.120.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.003.690.260.120.00
Proceedsfrom Stock Options0.003.690.000.000.000.00
Issuance or Reduction of Debt, Net-0.07-0.10-0.10-0.07-0.08-0.12
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-0.07-0.103.590.200.04-0.12
Net Change in Cash-1.64-1.491.97-1.24-1.61-1.72
Free Cash Flow-1.52-1.34-1.56-1.36-1.56-1.59

Revenue breakdown

In Vitro & In Vivo Diagnostic Substances2024: 34.89K 2025: 14.83K
United States2024: 34.89K 2025: 14.83K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.17%0.0M2.8M36.19K
2026-10-150.10%0.0M2.8M56.61K
2026-09-300.04%0.0M2.8M56.70K
2026-09-150.19%0.0M2.8M58.58K
2026-08-310.83%0.0M2.8M63.75K
2026-08-141.04%0.0M2.8M69.77K
2026-07-310.84%0.0M2.8M73.03K
2026-07-150.16%0.0M2.8M56.32K
2026-06-300.71%0.0M2.8M66.95K
2026-06-150.52%0.0M2.8M113.01K
2026-05-290.68%0.0M2.8M238.06K
2026-05-150.67%0.0M2.8M3.58M
2026-04-301.65%0.0M2.8M3.64M
2026-04-151.89%0.1M2.8M3.72M
2026-03-310.81%0.0M2.8M4.07M
2026-03-135.82%0.2M2.8M4.02M
2026-02-2730.05%0.5M1.7M3.82M
2026-02-137.21%0.1M1.7M418.96K
2026-01-308.50%0.1M1.7M405.63K
2026-01-157.86%0.1M1.7M380.10K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-09-188-KCurrent report2026-09-18SEC
2026-09-08DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-08-208-KCurrent report2026-08-20SEC
2026-08-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-07DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-08-05DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-18SEC
2026-07-23ARSAnnual report to security holders. 2025-12-31SEC
2026-07-13PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-09-18SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-04-024Statement of changes in beneficial ownership of securities2026-03-31SEC
2026-04-024Statement of changes in beneficial ownership of securities2026-03-31SEC
2026-04-024Statement of changes in beneficial ownership of securities2026-03-31SEC
2026-04-024Statement of changes in beneficial ownership of securities2026-03-31SEC
2026-03-1310-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-02-198-KCurrent report2026-02-19SEC
2026-01-064Statement of changes in beneficial ownership of securities2025-12-31SEC
2026-01-064Statement of changes in beneficial ownership of securities2025-12-31SEC
2026-01-064Statement of changes in beneficial ownership of securities2025-12-31SEC
2026-01-064Statement of changes in beneficial ownership of securities2025-12-31SEC
2025-11-1210-QQuarterly report pursuant to Section 13 or 15(d)2025-09-30SEC
2025-10-158-KCurrent report2025-10-15SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
RENAISSANCE TECHNOLOGIES LLC1.66%
BlackRock, Inc.1.17%
GEODE CAPITAL MANAGEMENT, LLC0.88%
VANGUARD CAPITAL MANAGEMENT LLC0.68%
CITADEL ADVISORS LLC0.64%
XTX Topco Ltd0.54%
JANE STREET GROUP, LLC0.40%
STATE STREET CORP0.34%
VANGUARD FIDUCIARY TRUST CO0.10%
Tower Research Capital LLC0.06%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.68%
Fidelity Extended Market Index Fund0.53%
Fidelity Series Total Market Index Fund0.10%
Fidelity Total Market Index Fund0.08%
Fidelity Nasdaq Composite Index Fund0.01%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. CDIO. Cached 15 minutes.

Some panels did not load: ratings, insider.